Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Neal

Showing results (411-420 of 484) with videos related to

Pageof 49
Sort By:
Diabetes Care|June 16, 2018
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary SyndromeIlse C Schrieks, Anna Nozza, Barbara E Stähli, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
The Lancet. Neurology|February 18, 2014
Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trialLisa Manning, Yoichiro Hirakawa, Hisatomi Arima, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
Diabetes Care|August 5, 2009
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trialSophia Zoungas, Bastiaan E de Galan, Toshiharu Ninomiya, et al.
The New England Journal of Medicine|May 30, 2013
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhageCraig S Anderson, Emma Heeley, Yining Huang, et al.
Heart (British Cardiac Society)|August 8, 2023
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressureEmily R Atkins, Alexander Chye, Thomas Lung, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Journal of the American Society of Nephrology : JASN|February 20, 2009
Lowering blood pressure reduces renal events in type 2 diabetesBastiaan E de Galan, Vlado Perkovic, Toshiharu Ninomiya, et al.
European Journal of Preventive Cardiology|March 29, 2014
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease riskAnushka Patel, Alan Cass, David Peiris, et al.
Pageof 49

Showing results (411-420 of 484) with videos related to

Sort By:
Pageof 49
Diabetes Care|June 16, 2018
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary SyndromeIlse C Schrieks, Anna Nozza, Barbara E Stähli, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
The Lancet. Neurology|February 18, 2014
Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trialLisa Manning, Yoichiro Hirakawa, Hisatomi Arima, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
Diabetes Care|August 5, 2009
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trialSophia Zoungas, Bastiaan E de Galan, Toshiharu Ninomiya, et al.
The New England Journal of Medicine|May 30, 2013
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhageCraig S Anderson, Emma Heeley, Yining Huang, et al.
Heart (British Cardiac Society)|August 8, 2023
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressureEmily R Atkins, Alexander Chye, Thomas Lung, et al.
Journal of the American Heart Association|June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE TrialsRobert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Journal of the American Society of Nephrology : JASN|February 20, 2009
Lowering blood pressure reduces renal events in type 2 diabetesBastiaan E de Galan, Vlado Perkovic, Toshiharu Ninomiya, et al.
European Journal of Preventive Cardiology|March 29, 2014
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease riskAnushka Patel, Alan Cass, David Peiris, et al.
Pageof 49